Latest Competition News

Webjet’s board has unanimously dismissed BGH’s unsolicited acquisition offer, citing undervaluation and significant uncertainties. The company remains open to proposals that better serve shareholder interests.

Appen Limited reported robust 2024 results with a 16% revenue increase excluding Google and a return to profitability, driven by generative AI projects and China market expansion. The company outlines a confident 2025 strategy focused on AI data quality, operational efficiency, and sustained growth.

Capstone 510 Copper Georgia Corp. has amended its revolving credit facility, increasing its size to $1 billion and extending the maturity date to May 2029, enhancing its financial flexibility for ongoing projects.

Moho Resources has identified a significant 4 km by 1 km gold soil anomaly at its Silver Swan North Project in Western Australia’s Eastern Goldfields, marking a promising new chapter in the company’s exploration efforts.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Aspen Group announces a $74 million equity raise alongside robust earnings growth and unchanged FY25 guidance, positioning itself for expansion in Australia’s tight housing market.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Peak Rare Earths is poised for acquisition by Shenghe Resources in a deal valuing the company at A$150.5 million, supported by a A$7.5 million entitlement offer to fund ongoing development and transaction costs.

Peak Rare Earths Limited has agreed to be acquired by Ganzhou Chenguang Rare Earths New Material Co., Ltd., a subsidiary of Shenghe Resources, in a deal valuing Peak at A$150.5 million plus proceeds from a proposed entitlement offer. The transaction offers Peak shareholders a significant premium and aims to accelerate development of the Ngualla Rare Earth Project.

Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.